Literature DB >> 22072774

Arterivirus and nairovirus ovarian tumor domain-containing Deubiquitinases target activated RIG-I to control innate immune signaling.

Puck B van Kasteren1, Corrine Beugeling, Dennis K Ninaber, Natalia Frias-Staheli, Sander van Boheemen, Adolfo García-Sastre, Eric J Snijder, Marjolein Kikkert.   

Abstract

The innate immune response constitutes the first line of defense against viral infection and is extensively regulated through ubiquitination. The removal of ubiquitin from innate immunity signaling factors by deubiquitinating enzymes (DUBs) therefore provides a potential opportunity for viruses to evade this host defense system. It was previously found that specific proteases encoded by the unrelated arteri- and nairoviruses resemble the ovarian tumor domain-containing (OTU) family of DUBs. In arteriviruses, this domain has been characterized before as a papain-like protease (PLP2) that is also involved in replicase polyprotein processing. In nairoviruses, the DUB resides in the polymerase protein but is not essential for RNA replication. Using both in vitro and cell-based assays, we now show that PLP2 DUB activity is conserved in all members of the arterivirus family and that both arteri- and nairovirus DUBs inhibit RIG-I-mediated innate immune signaling when overexpressed. The potential relevance of RIG-I-like receptor (RLR) signaling for the innate immune response against arterivirus infection is supported by our finding that in mouse embryonic fibroblasts, the production of beta interferon primarily depends on the recognition of arterivirus RNA by the pattern-recognition receptor MDA5. Interestingly, we also found that both arteri- and nairovirus DUBs inhibit RIG-I ubiquitination upon overexpression, suggesting that both MDA5 and RIG-I have a role in countering infection by arteriviruses. Taken together, our results support the hypothesis that arteri- and nairoviruses employ their deubiquitinating potential to inactivate cellular proteins involved in RLR-mediated innate immune signaling, as exemplified by the deubiquitination of RIG-I.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22072774      PMCID: PMC3255818          DOI: 10.1128/JVI.06277-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  75 in total

1.  Murine coronavirus induces type I interferon in oligodendrocytes through recognition by RIG-I and MDA5.

Authors:  Jianfeng Li; Yin Liu; Xuming Zhang
Journal:  J Virol       Date:  2010-04-28       Impact factor: 5.103

2.  The cysteine protease domain of porcine reproductive and respiratory syndrome virus nonstructural protein 2 possesses deubiquitinating and interferon antagonism functions.

Authors:  Zhi Sun; Zhenhai Chen; Steven R Lawson; Ying Fang
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

Review 3.  The feasibility of developing a risk assessment for the impact of climate change on the emergence of Crimean-Congo haemorrhagic fever in livestock in Europe: a review.

Authors:  P Gale; A Estrada-Peña; M Martinez; R G Ulrich; A Wilson; G Capelli; P Phipps; A de la Torre; M J Muñoz; M Dottori; V Mioulet; A R Fooks
Journal:  J Appl Microbiol       Date:  2009-11-28       Impact factor: 3.772

Review 4.  Central roles of NLRs and inflammasomes in viral infection.

Authors:  Thirumala-Devi Kanneganti
Journal:  Nat Rev Immunol       Date:  2010-09-17       Impact factor: 53.106

5.  Inhibition of the type I interferon response in human dendritic cells by dengue virus infection requires a catalytically active NS2B3 complex.

Authors:  Juan R Rodriguez-Madoz; Alan Belicha-Villanueva; Dabeiba Bernal-Rubio; Joseph Ashour; Juan Ayllon; Ana Fernandez-Sesma
Journal:  J Virol       Date:  2010-07-21       Impact factor: 5.103

6.  Papain-like protease 1 from transmissible gastroenteritis virus: crystal structure and enzymatic activity toward viral and cellular substrates.

Authors:  Justyna A Wojdyla; Ioannis Manolaridis; Puck B van Kasteren; Marjolein Kikkert; Eric J Snijder; Alexander E Gorbalenya; Paul A Tucker
Journal:  J Virol       Date:  2010-07-28       Impact factor: 5.103

7.  RIG-I is cleaved during picornavirus infection.

Authors:  Paola M Barral; Devanand Sarkar; Paul B Fisher; Vincent R Racaniello
Journal:  Virology       Date:  2009-07-22       Impact factor: 3.616

8.  Ubiquitin-regulated recruitment of IkappaB kinase epsilon to the MAVS interferon signaling adapter.

Authors:  Suzanne Paz; Myriam Vilasco; Meztli Arguello; Qiang Sun; Judith Lacoste; Thi Lien-Anh Nguyen; Tiejun Zhao; Elena A Shestakova; Scott Zaari; Annie Bibeau-Poirier; Marc J Servant; Rongtuan Lin; Eliane F Meurs; John Hiscott
Journal:  Mol Cell Biol       Date:  2009-04-20       Impact factor: 4.272

9.  Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-kappaB signaling.

Authors:  Matthew Frieman; Kiira Ratia; Robert E Johnston; Andrew D Mesecar; Ralph S Baric
Journal:  J Virol       Date:  2009-04-15       Impact factor: 5.103

10.  The porcine reproductive and respiratory syndrome virus nsp2 cysteine protease domain possesses both trans- and cis-cleavage activities.

Authors:  Jun Han; Mark S Rutherford; Kay S Faaberg
Journal:  J Virol       Date:  2009-07-08       Impact factor: 5.103

View more
  76 in total

1.  The ubiquitin-specific protease USP15 promotes RIG-I-mediated antiviral signaling by deubiquitylating TRIM25.

Authors:  Eva-Katharina Pauli; Ying Kai Chan; Meredith E Davis; Sebastian Gableske; May K Wang; Katharina F Feister; Michaela U Gack
Journal:  Sci Signal       Date:  2014-01-07       Impact factor: 8.192

2.  Insights into the Porcine Reproductive and Respiratory Syndrome Virus Viral Ovarian Tumor Domain Protease Specificity for Ubiquitin and Interferon Stimulated Gene Product 15.

Authors:  Stephanie M Bester; Courtney M Daczkowski; Kay S Faaberg; Scott D Pegan
Journal:  ACS Infect Dis       Date:  2018-06-12       Impact factor: 5.084

Review 3.  Structural Variability in the RLR-MAVS Pathway and Sensitive Detection of Viral RNAs.

Authors:  Qiu-Xing Jiang
Journal:  Med Chem       Date:  2019       Impact factor: 2.745

4.  Diversity of ubiquitin and ISG15 specificity among nairoviruses' viral ovarian tumor domain proteases.

Authors:  Glenn C Capodagli; Michelle K Deaton; Erica A Baker; Ryan J Lumpkin; Scott D Pegan
Journal:  J Virol       Date:  2013-01-23       Impact factor: 5.103

5.  Deubiquitinase function of arterivirus papain-like protease 2 suppresses the innate immune response in infected host cells.

Authors:  Puck B van Kasteren; Ben A Bailey-Elkin; Terrence W James; Dennis K Ninaber; Corrine Beugeling; Mazdak Khajehpour; Eric J Snijder; Brian L Mark; Marjolein Kikkert
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-11       Impact factor: 11.205

Review 6.  Mechanisms of RIG-I-like receptor activation and manipulation by viral pathogens.

Authors:  Michaela U Gack
Journal:  J Virol       Date:  2014-03-12       Impact factor: 5.103

7.  Fluorometric CCHFV OTU protease assay with potent inhibitors.

Authors:  Fatih Kocabas; Galip S Aslan
Journal:  Virus Genes       Date:  2015-07-09       Impact factor: 2.332

Review 8.  Deubiquitinating enzymes as promising drug targets for infectious diseases.

Authors:  Bindu Nanduri; Akamol E Suvarnapunya; Malabi Venkatesan; Mariola J Edelmann
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

9.  Efficient -2 frameshifting by mammalian ribosomes to synthesize an additional arterivirus protein.

Authors:  Ying Fang; Emmely E Treffers; Yanhua Li; Ali Tas; Zhi Sun; Yvonne van der Meer; Arnoud H de Ru; Peter A van Veelen; John F Atkins; Eric J Snijder; Andrew E Firth
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-04       Impact factor: 11.205

10.  The papain-like protease of porcine epidemic diarrhea virus negatively regulates type I interferon pathway by acting as a viral deubiquitinase.

Authors:  Yaling Xing; Jianfei Chen; Jian Tu; Bailing Zhang; Xiaojuan Chen; Hongyan Shi; Susan C Baker; Li Feng; Zhongbin Chen
Journal:  J Gen Virol       Date:  2013-04-17       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.